| Primary | Change in Maximal Postural Tachycardia During Tilt | Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. | | Posted | | | | | | Up to 3 days after randomization | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | Change Maximal Postural Tachycardia During Tilt | Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. | | Posted | | | | | | 2 weeks after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Primary | Change Maximal Postural Tachycardia During Tilt | Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. | | Posted | | | | | | 2 weeks after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Primary | Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline | A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. | | Posted | | | | | | up to 3 days after randomization | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Primary | Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline | A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. | | Posted | | | | | | 2 weeks after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Primary | Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline | A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. | | Posted | | | | | | 2 weeks after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Blood Pressure From Baseline | | | Posted | | | | | | 1 week after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Blood Pressure From Baseline | | | Posted | | | | | | 1 week after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Blood Pressure From Baseline | | | Posted | | | | | | 1 week after third intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Heart Rate From Baseline | | | Posted | | | | | | 1 week after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Heart Rate From Baseline | | | Posted | | | | | | 1 week after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Heart Rate From Baseline | | | Posted | | | | | | 1 week after third intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Vascular Resistance From Baseline | | | Posted | | | | | | 1 week after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Vascular Resistance From Baseline | | | Posted | | | | | | 1 week after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Vascular Resistance From Baseline | | | Posted | | | | | | 1 week after third intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Muscle Sympathetic Nerve Activity From Baseline | | | Posted | | | | | | 1 week after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Muscle Sympathetic Nerve Activity From Baseline | | | Posted | | | | | | 1 week after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Muscle Sympathetic Nerve Activity From Baseline | | | Posted | | | | | | 1 week after third intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-SF-36 Q From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. | | Posted | | | | | | 1 week after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-SF-36 Q From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. | | Posted | | | | | | 1 week after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-SF-36 Q From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. | | Posted | | | | | | 1 week after third intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better" to "very much worse". | | Posted | | | | | | 1 week after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better" to "very much worse". | | Posted | | | | | | 1 week after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better" to "very much worse". | | Posted | | | | | | 1 week after third intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning- HADS From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. | | Posted | | | | | | 1 week after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning- HADS From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. | | Posted | | | | | | 1 week after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning- HADS From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. | | Posted | | | | | | 1 week after third intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-CIS From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). | | Posted | | | | | | 1 week after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-CIS From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). | | Posted | | | | | | 1 week after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-CIS From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). | | Posted | | | | | | 1 week after third intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-MFI From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). | | Posted | | | | | | 1 week after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-MFI From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). | | Posted | | | | | | 1 week after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-MFI From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). | | Posted | | | | | | 1 week after third intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-FSS From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. | | Posted | | | | | | 1 week after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-FSS From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. | | Posted | | | | | | 1 week after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-FSS From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. | | Posted | | | | | | 1 week after third intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-EuroQOL From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. | | Posted | | | | | | 1 week after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-EuroQOL From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. | | Posted | | | | | | 1 week after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-EuroQOL From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. | | Posted | | | | | | 1 week after third intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-OI From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. | | Posted | | | | | | 1 week after first intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-OI From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. | | Posted | | | | | | 1 week after second intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|
| Secondary | Change in Physical Functioning-OI From Baseline | Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. | | Posted | | | | | | 1 week after third intervention | | | | ID | Title | Description |
|---|
| OG000 | Atenolol | In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d | | OG001 | Placebos | In this arm subjects are randomized to placebo tid. Placebo is used to control the administration effect. Placebos: Placebo: t.i.d | | OG002 | Droxidopa | In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid. Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients. Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients. Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d Atenolol: Atenolol: 50 mg Q.D. Placebos: Placebo: t.i.d |
|